Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
Current advances in understanding of the pathogenesis of inflammatory bowel disease have encouraged the development of many new therapies targeted at specific and non-specific mediators of the inflammatory bowel disease inflammatory pathway. Crohn's disease and ulcerative colitis, two common inflammatory bowel diseases likely result from interaction of multiple genetic and environmental risk and protective factors, deregulation of mucosal immunity in gut and breakdown of delicate balance of proinflammatory and anti-inflammatory cytokines. Immunobiologic agents targeted against TNF, leukocyte adhesion, Th1 polarization, T cell activation, nuclear factor-kappaB (NF-kappaB), and others are being assessed and will open exciting perspectives on development of therapies for inflammatory bowel disease.
Ghosh
Nilanjan
N
Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Durgapur, India. bhu nils@rediffmail.com
Chaki
Rituparna
R
Mandal
Vivekananda
V
Lin
G David
GD
Mandal
Subhash C
SC
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000235:genetics / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D003424:Crohn Disease / Q000235:genetics / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D016207:Cytokines / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology* / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000235:genetics / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007155:Immunologic Factors